CAT, Genzyme announce preliminary results from trial of CAT-192 for Scleroderma
Wednesday, February 11, 2004 16:30 IST Cambridge
Cambridge Antibody Technology (CAT) and Genzyme Corp announce preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGFß1 monoclonal antibody